Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00935766 · ClinicalTrials.gov registry record · Phase 3
Effect of Fish Oil (Omega-3 Fatty Acids) on Arteries
A Phase 3 study, sponsored by Denver Health and Hospital Authority.
- Terminated
- Registry status
- Phase 3
- Development phase
- 76
- Enrollment target
NCT00935766 is a Phase 3 study that was terminated before completion, run by Denver Health and Hospital Authority. The registered enrollment target is 76 participants.
The verdict
NCT00935766, a Phase 3 study, was terminated before completion, sponsored by Denver Health and Hospital Authority.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 76 participants
- Enrollment target
Study Summary
The overall objective of LUCHAR Specific Aims 4.1 and 4.2 is to assess the additional contribution of cardiovascular disease (CVD) risk markers to traditional biomedical risk factors in the prediction of pre-clinical CVD. Specific Aim 4.3 will test the impact of omega-3 fatty acid supplementation on risk markers and pre-clinical markers of CVD in Hispanic patients. Specific Aim 4.3: Conduct a randomized, placebo-controlled trial of the effect of omega-3 fatty acid supplementation on vascular function as measured by brachial artery reactivity (BAR) and on circulating inflammatory markers. Hypotheses: 1. Daily omega-3 fatty acid supplementation will improve vascular function in subjects at high risk for CVD. 2. Daily omega-3 fatty acid supplementation will reduce inflammatory protein panel scores in subjects at high risk for CVD.
Interventions
- DRUG Placebo
- DRUG Omega-3
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 76 participants |
| Start Date | 2009-09 |
| Est. Completion | 2012-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00935766
The ClinicalTrials.gov registry entry for NCT00935766 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 76 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Denver Health and Hospital Authority, which has 73 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00935766 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00935766 about?
NCT00935766 is a clinical study titled "Effect of Fish Oil (Omega-3 Fatty Acids) on Arteries". The overall objective of LUCHAR Specific Aims 4.1 and 4.2 is to assess the additional contribution of cardiovascular disease (CVD) risk markers to traditional biomedical risk factors in the prediction of pre-clinical CVD. Specific Aim 4.3 will test the impact of omega-3 fatty acid supplementation on...
What is the current status of trial NCT00935766?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 76 participants. The study started on 2009-09. Estimated completion is 2012-03.
What interventions are being tested in trial NCT00935766?
The interventions under investigation include: Placebo (DRUG), Omega-3 (DRUG).
Who is sponsoring clinical trial NCT00935766?
This trial is sponsored by Denver Health and Hospital Authority, which has 73 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.